Triastek
T25 is an oral octreotide acetate tablet. MED&SSE produces its shell and drug-containing core; FDA IND clearance was disclosed in 2026.
Corporate information
- Company entity
- Triastek, Inc.／南京三迭纪生物科技有限公司
- Headquarters / principal office
- Nanjing, JiangsuSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2015 ↗
- Ownership / capital status
- PrivateStrategic equity investment (announced in 2026) ↗
- Official corporate reference
- https://www.triastek.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2026-10-09 · Strategic equity investment by JJDC · Amount not disclosed ↗
The announcement states that JJDC will invest; closing and the amount were not disclosed. A $20.4 million pre-Series C round was previously announced on 2023-09-28.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
T25 uses MED&SSE and the 3DμS®-OM system for maintenance treatment of acromegaly.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.